Background: Coronavirus disease 2019 (COVID-19) pneumonia and immune checkpoint inhibitor (ICI) therapy-related pneumonitis share common features. The aim of this study was to determine on chest computed tomography (CT) images whether a deep convolutional neural network algorithm is able to solve the challenge of differential diagnosis between COVID-19 pneumonia and ICI therapy-related pneumonitis. Methods: We enrolled three groups: a pneumonia-free group (n = 30), a COVID-19 group (n = 34), and a group of patients with ICI therapy-related pneumonitis (n = 21). Computed tomography images were analyzed with an artificial intelligence (AI) algorithm based on a deep convolutional neural network structure. Statistical analysis included the Mann– Whitney U test (significance threshold at p < 0.05) and the receiver operating characteristic curve (ROC curve). Results: The algorithm showed low specificity in distinguishing COVID-19 from ICI therapy-related pneumonitis (sensitivity 97.1%, specificity 14.3%, area under the curve (AUC) = 0.62). ICI therapy-related pneumonitis was identified by the AI when compared to pneumonia-free controls (sensitivity = 85.7%, specificity 100%, AUC = 0.97). Conclusions: The deep learning algorithm is not able to distinguish between COVID-19 pneumonia and ICI therapy-related pneumonitis. Awareness must be increased among clinicians about imaging similarities between COVID-19 and ICI therapy related pneumonitis. ICI therapy-related pneumonitis can be applied as a challenge population for cross-validation to test the robustness of AI models used to analyze interstitial pneumonias of variable etiology.

Deep learning algorithm trained with COVID-19 pneumonia also identifies immune checkpoint inhibitor therapy-related pneumonitis / Mallio, Ca; Napolitano, A; Castiello, G; Giordano, Fm; D'Alessio, P; Iozzino, M; Sun, Yp; Angeletti, S; Russano, M; Santini, D; Tonini, G; Beomonte Zobel, B; Vincenzi, B; Quattrocchi, Cc. - In: CANCERS. - ISSN 2072-6694. - 13:4(2021), pp. 1-12. [10.3390/cancers13040652]

Deep learning algorithm trained with COVID-19 pneumonia also identifies immune checkpoint inhibitor therapy-related pneumonitis

Santini D;
2021

Abstract

Background: Coronavirus disease 2019 (COVID-19) pneumonia and immune checkpoint inhibitor (ICI) therapy-related pneumonitis share common features. The aim of this study was to determine on chest computed tomography (CT) images whether a deep convolutional neural network algorithm is able to solve the challenge of differential diagnosis between COVID-19 pneumonia and ICI therapy-related pneumonitis. Methods: We enrolled three groups: a pneumonia-free group (n = 30), a COVID-19 group (n = 34), and a group of patients with ICI therapy-related pneumonitis (n = 21). Computed tomography images were analyzed with an artificial intelligence (AI) algorithm based on a deep convolutional neural network structure. Statistical analysis included the Mann– Whitney U test (significance threshold at p < 0.05) and the receiver operating characteristic curve (ROC curve). Results: The algorithm showed low specificity in distinguishing COVID-19 from ICI therapy-related pneumonitis (sensitivity 97.1%, specificity 14.3%, area under the curve (AUC) = 0.62). ICI therapy-related pneumonitis was identified by the AI when compared to pneumonia-free controls (sensitivity = 85.7%, specificity 100%, AUC = 0.97). Conclusions: The deep learning algorithm is not able to distinguish between COVID-19 pneumonia and ICI therapy-related pneumonitis. Awareness must be increased among clinicians about imaging similarities between COVID-19 and ICI therapy related pneumonitis. ICI therapy-related pneumonitis can be applied as a challenge population for cross-validation to test the robustness of AI models used to analyze interstitial pneumonias of variable etiology.
2021
artificial intelligence; COVID-19; deep learning; chest CT; immune checkpoint inhibitors therapy; drug-induced pneumonitis
01 Pubblicazione su rivista::01a Articolo in rivista
Deep learning algorithm trained with COVID-19 pneumonia also identifies immune checkpoint inhibitor therapy-related pneumonitis / Mallio, Ca; Napolitano, A; Castiello, G; Giordano, Fm; D'Alessio, P; Iozzino, M; Sun, Yp; Angeletti, S; Russano, M; Santini, D; Tonini, G; Beomonte Zobel, B; Vincenzi, B; Quattrocchi, Cc. - In: CANCERS. - ISSN 2072-6694. - 13:4(2021), pp. 1-12. [10.3390/cancers13040652]
File allegati a questo prodotto
File Dimensione Formato  
Mallio_Deep-learning_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 5.91 MB
Formato Adobe PDF
5.91 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1642321
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact